Harold Tara Jr, MD

Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. Journal Of Oncology Practice / American Society Of Clinical Oncology 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/JOP.18.00419.

Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. Journal Of Immunotherapy (Hagerstown, Md. : 1997) 2008, 31: 569-76. PMID: 18528297, DOI: 10.1097/CJI.0b013e318177a4ba.

Kamath A, Tara H, Xiang B, Bajaj R, He W, Li P. Double-minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B, and ELAVL2 in an acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization. Cancer Genetics And Cytogenetics 2008, 183: 117-20. PMID: 18503831, DOI: 10.1016/j.cancergencyto.2008.02.011.

Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biology & Therapy 2002, 1: 646-51. PMID: 12642688, DOI: 10.4161/cbt.314.